Climb Bio (NASDAQ:CLYM - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Monday.
A number of other analysts have also recently weighed in on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Climb Bio in a research note on Saturday, September 27th. BTIG Research upped their price objective on Climb Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Tuesday, September 30th. Baird R W upgraded shares of Climb Bio to a "strong-buy" rating in a report on Friday, August 15th. Finally, Robert W. Baird assumed coverage on shares of Climb Bio in a report on Friday, August 15th. They issued an "outperform" rating and a $9.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $9.25.
Get Our Latest Report on Climb Bio
Climb Bio Price Performance
CLYM stock opened at $1.98 on Monday. The company has a 50-day moving average of $2.05 and a two-hundred day moving average of $1.54. The stock has a market capitalization of $134.16 million, a price-to-earnings ratio of -2.83 and a beta of -0.07. Climb Bio has a 52-week low of $1.05 and a 52-week high of $5.47.
Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.06. Equities analysts expect that Climb Bio will post -1.57 EPS for the current fiscal year.
Institutional Trading of Climb Bio
A number of institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. bought a new stake in Climb Bio in the 1st quarter valued at about $38,332,000. Affinity Asset Advisors LLC bought a new stake in shares of Climb Bio during the 1st quarter worth approximately $1,830,000. Diadema Partners LP lifted its holdings in shares of Climb Bio by 4.8% during the 2nd quarter. Diadema Partners LP now owns 702,135 shares of the company's stock worth $871,000 after acquiring an additional 32,332 shares during the period. Peapod Lane Capital LLC bought a new stake in shares of Climb Bio during the 1st quarter worth approximately $676,000. Finally, Nan Fung Trinity HK Ltd. bought a new stake in shares of Climb Bio during the 2nd quarter worth approximately $575,000. Institutional investors own 69.76% of the company's stock.
About Climb Bio
(
Get Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.